CYTRX CP
			Symbol			CYTR

This item is part of Stockwatch's value added news feed and is only available to Stockwatch subscribers.

Here is a sample of this item:

Pending Key Developments Ahead for CytRx Corporation (NASDAQ: CYTR)

2009-11-23 10:38 ET - News Release

LOS ANGELES, CA -- (MARKET WIRE) -- 11/23/09

BioMedReports.Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors, has issued a special report on CytRx Corporation (NASDAQ: CYTR).

The stock, which has traded as low as $.24 earlier this year, appears to be on the rebound with at least two key developments on the horizon.

On Friday, after seeing the stock gap up on heavy volume, rumors began to swirl throughout cyberspace and on message boards about pending good news. Earlier in the week, shares of the company, whose drug development pipeline includes two product candidates in clinical development for cancer indications and treatments for neurodegenerative and other disorders based on its small-molecule molecular chaperone amplification technology, had barely registered a blip on the radar screen.

The remainder is available to Stockwatch subscribers.
If you would like to give the Stockwatch system a try, click here for a free 30 day trial subscription.